Table 5.
Comparison of patient characteristics with normal geometry versus concentric remodeling.
| LVM/BSAASE cohort | LVM/height2.7 cohort | LVM/BSACT cohort | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Normal geometry | Concentric remodeling | p-value | Normal geometry | Concentric remodeling | p-value | Normal geometry | Concentric remodeling | p-value | |
| Demographics, n (%) | 272 (81.2%) | 63 (18.8%) | 265 (81.8%) | 59 (18.2%) | 264 (81.5%) | 60 (18.5%) | |||
| Age, yrs | 52.4 ±11.5 | 53.6 ± 11.7 | 0.43 | 52.3 ± 11.5 | 53.3 ± 12.2 | 0.55 | 52.3 ± 11.5 | 53.8 ± 11.7 | 0.37 |
| Gender, male (%) | 152 (55.9%) | 53 (84.1%) | <0.0001 | 146 (55.1%) | 50 (84.8%) | <0.0001 | 146 (55.3%) | 51 (85.0%) | <0.0001 |
| Race, black (%) | 24 (8.8%) | 6 (9.5%) | 0.81 | 23 (8.7%) | 4 (6.8%) | 0.80 | 24 (9.1%) | 5 (8.3%) | 0.85 |
| Body mass index, kg/m2 | 28.7 ± 5.7 | 30.0 ± 6.1 | 0.12 | 28.5 ± 5.5 | 29.1 ± 5.1 | 0.50 | 28.7 ± 5.7 | 29.9 ± 6.2 | 0.14 |
| Risk factors | |||||||||
| Hypertension (%) | 94 (34.6%) | 32 (50.8%) | 0.02 | 88 (33.2%) | 28 (47.5%) | 0.04 | 90 (34.1%) | 30 (50.0%) | 0.02 |
| Diabetes (%) | 26 (9.6%) | 7 (11.1%) | 0.65 | 24 (9.1%) | 5 (8.5%) | 0.89 | 23 (8.7%) | 6 (10.0%) | 0.75 |
| Hyperlipidemia (%) | 98 (36.0%) | 21 (33.3%) | 0.77 | 94 (35.5%) | 19 (32.2%) | 0.76 | 94 (35.6%) | 20 (33.3%) | 0.74 |
| History of CAD (%) | 13 (4.8%) | 3 (4.8%) | 1.0 | 13 (4.9%) | 3 (5.1%) | 1.0 | 12 (4.6%) | 3 (5.0%) | 0.75 |
| Family history of CAD (%) | 59 (21.7%) | 24 (38.1%) | 0.009 | 57 (21.5%) | 23 (39.0%) | 0.007 | 57 (21.6%) | 23 (38.3%) | 0.007 |
| History of LV dysfunction (%) | 4 (1.5%) | 1 (1.6%) | 1.0 | 1 (1.5%) | 1 (1.7%) | 1.0 | 4 (1.5%) | 1 (1.7%) | 1.0 |
| Smokers (%) | 132 (48.5%) | 36 (57.1%) | 0.26 | 129 (48.7%) | 35 (59.3%) | 0.15 | 127 (48.1%) | 36 (60.0%) | 0.10 |
| Medications | |||||||||
| Aspirin (%) | 86 (31.6%) | 16 (25.4%) | 0.37 | 83 (31.3%) | 15 (25.4%) | 0.43 | 82 (31.1%) | 15 (25.0%) | 0.35 |
| Statin (%) | 74 (27.2%) | 16 (25.4%) | 0.88 | 70 (26.4%) | 14 (23.7%) | 0.74 | 71 (26.9%) | 15 (25.0%) | 0.76 |
| Hypertensive Medication (%) | 93 (34.2%) | 31 (49.2%) | 0.03 | 87 (32.8%) | 27 (45.8%) | 0.06 | 89 (33.7%) | 29 (48.3%) | 0.03 |
| Presenting Characteristics | |||||||||
| SBP, mmHg | 138 ± 22 | 139 ± 21 | 0.85 | 138 ± 22 | 137 ± 19 | 0.73 | 138 ± 22 | 138 ±18 | 0.91 |
| eGFR, ml/min/1.73 m2 | 85.0 ± 17.3 | 82.6 ± 18.3 | 0.33 | 84.7 ± 17.4 | 82.3 ± 18.5 | 0.35 | 84.8 ± 17.3 | 81.9 ± 18.2 | 0.24 |
| CT Measurements | |||||||||
| LV ejection fraction, % | 67.5 ± 9.5 | 69.8 ± 7.6 | 0.07 | 67.5 ± 9.5 | 69.7 ± 7.8 | 0.09 | 67.6 ± 9.5 | 70.1 ± 7.7 | 0.05 |
| RWT ratio | 0.33 ± 0.05 | 0.50 ± 0.07 | <0.0001 | 0.33 ± 0.05 | 0.50 ± 0.07 | <0.0001 | 0.33 ± 0.05 | 0.50 ± 0.07 | <0.0001 |
Abbreviations as in Table 1.